Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Sachdev Thomas"'
Autor:
Scott A. Tomlins, Nickolay A. Khazanov, Benjamin J. Bulen, Daniel H. Hovelson, Melissa J. Shreve, Laura E. Lamb, Marc R. Matrana, Mark E. Burkard, Eddy Shih-Hsin Yang, William Jeffery Edenfield, E. Claire Dees, Adedayo A. Onitilo, Michael Thompson, Gary L. Buchschacher, Alan M. Miller, Alexander Menter, Benjamin Parsons, Timothy Wassenaar, Leon C. Hwang, J. Marie Suga, Robert Siegel, William Irvin, Suresh Nair, Jennifer N. Slim, Jamal Misleh, Jamil Khatri, Gregory Masters, Sachdev Thomas, Malek Safa, Daniel M. Anderson, Kat Kwiatkowski, Khalis Mitchell, Tina Hu-Seliger, Stephanie Drewery, Andrew Fischer, Komal Plouffe, Eric Czuprenski, Jennifer Hipp, Travis Reeder, Hana Vakil, D. Bryan Johnson, Daniel R. Rhodes
Publikováno v:
Communications Medicine, Vol 3, Iss 1, Pp 1-14 (2023)
Tomlins et al. develop an Immunotherapy Response Score (IRS) to predict clinical benefit from checkpoint inhibition across solid tumors. IRS integrates TMB and gene expression, is evaluable from FFPE material, and is predictive for real-world progres
Externí odkaz:
https://doaj.org/article/4592ab4c5780454fabd8956daa3f8f79
Autor:
Minggui Pan, Chen Jiang, Zheyang Zhang, Ninah Achacoso, Aleyda V. Solorzano-Pinto, Pam Tse, Elaine Chung, Jennifer Marie Suga, Sachdev Thomas, Laurel A. Habel
Publikováno v:
Cancers, Vol 15, Iss 10, p 2665 (2023)
Background: Whether sex and co-mutations impact prognosis of patients with SMARCA4-mutated (mutSMARCA4) malignancies is not clear. Methods: This cohort included patients from Northern California Kaiser Permanente with next-generation sequencing (NGS)
Externí odkaz:
https://doaj.org/article/6a18d512108c4ab781179a05aa0aad4d
Autor:
Minggui Pan, Chen Jiang, Zheyang Zhang, Ninah Achacoso, Stacey Alexeeff, Aleyda V. Solorzano, Pam Tse, Elaine Chung, Tilak Sundaresan, Jennifer Marie Suga, Sachdev Thomas, Laurel A. Habel
Publikováno v:
JCO Precision Oncology.
PURPOSE To examine the impact of TP53 gain-of-function (GOF) and non-GOF mutations on prognosis of advanced pancreatic ductal adenocarcinoma (PDAC) among patients with KRAS, CDKN2A, and SMAD4 comutations. METHODS This cohort included patients with lo
Publikováno v:
Gastro – Open Journal. 3:1-3
Autor:
D. Ross Camidge, Ekaterine Alexandris, Sachdev Thomas, J. Goldschmidt, Frederique Bustin, Philip Bonomi, David R. Spigel, Janice F. Eakle, Mustapha Tehfe, Sunil Verma, Martin Reck, Robert C. Doebele, Sergey Yurasov, Dachuang Cao
Publikováno v:
Cancer. 121:883-892
BACKGROUND Vascular endothelial growth factor (VEGF)–mediated angiogenesis plays an important role in non–small cell lung cancer (NSCLC). Ramucirumab is a human immunoglobulin G1 monoclonal antibody that inhibits VEGF receptor 2. This phase 2 stu
Autor:
Elaine W. Yu, George Dranitsaris, Arliene Ravelo, Nancy Beegle, Sachdev Thomas, Traci L. Kalberer
Publikováno v:
Clinical Lung Cancer. 14:120-127
Background In patients with advanced-stage non–small-cell lung cancer (NSCLC) with nonsquamous histology, bevacizumab maintenance therapy after initial combination with platinum-based chemotherapy has been approved in the United States and Europe.
Publikováno v:
Cureus
Epidermal growth factor receptor (EGFR) mutations and anaplastic large-cell lymphoma kinase (ALK) rearrangements are now routine biomarkers that have been incorporated into the practice of managing non-small cell lung cancer (NSCLC). Historically, th
Autor:
Subramanyeswara R. Arekapudi, Shreyas Saligram, Sachdev Thomas, Bishara Rizvi, Helen Wong, Madhav Desai
Publikováno v:
American Journal of Gastroenterology. 112:S96-S97
Autor:
Rita Axelrod, Rogerio Lilenbaum, Afshin Dowlati, David Botkin, Leonard Seigel, Donald Albert, Karsten Witt, Sachdev Thomas
Publikováno v:
Journal of Clinical Oncology. 26:863-869
Purpose A multicenter randomized phase II trial to evaluate two treatment strategies in the first-line management of advanced non–small-cell lung cancer (NSCLC) patients with a performance status (PS) of 2. Patients and Methods Patients were assign
Autor:
Robert C, Doebele, David, Spigel, Mustapha, Tehfe, Sachdev, Thomas, Martin, Reck, Sunil, Verma, Janice, Eakle, Frederique, Bustin, Jerome, Goldschmidt, Dachuang, Cao, Ekaterine, Alexandris, Sergey, Yurasov, D Ross, Camidge, Philip, Bonomi
Publikováno v:
Cancer. 121(6)
Vascular endothelial growth factor (VEGF)-mediated angiogenesis plays an important role in non-small cell lung cancer (NSCLC). Ramucirumab is a human immunoglobulin G1 monoclonal antibody that inhibits VEGF receptor 2. This phase 2 study investigated